WHO sees more evidence that Omicron affects upper respiratory tract
GENEVA, Jan 4 (Reuters) - More evidence is emerging that the
Omicron coronavirus variant is affecting the upper respiratory
tract, causing milder symptoms than previous variants, a World
Health Official said on Tuesday.
Asked about whether an Omicron-specific vaccine was needed,
WHO Incident Manager Abdi Mahamud said it was too early to say
but stressed that the decision required global coordination and
should not be left to the commercial sector to decide alone.
(Reporting by Emma Farge and Mrinalika Roy in Bangalore)
((emma.farge@thomsonreuters.com;))
Recent news on Sinopharm
See all newsBrief: Sinopharm Group Says 9M Sinopharm Accord Net Income Attributable RMB952.5 Million (Oct 20)
Medical products distributor Sinopharm Group's prelim 9-month revenue slips
Brief: BlackRock's Long Position In H Shares Of Sinopharm Reduces To 9.23% On Oct 13, HKEX Shows
Sinopharm interim revenue edges down on softness in pharmaceutical distribution business
Brief: Sinopharm Group To Sell 30.13% Stake In China National Medicines Guorui Pharmaceutical For